The Rheumatoid Arthritis Quality of Life Questionnaire
| The Rheumatoid Arthritis Quality of Life Questionnaire | |
|---|---|
| [[File:|250px|alt=|]] | |
| Pronunciation | |
| Synonyms | |
| Reference Range | |
| Calculator | |
| Purpose | determine quality of life with Rheumatoid Arthritis |
| Test of | |
| Based on | |
| ICD-10-PCS | |
| ICD-9-CM | |
| MeSH | |
| OPS-301 Code | |
| Other Codes | |
| MedlinePlus | |
| eMedicine | |
| LOINC | |
| HCPCS-L2 | |
The Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) is a disease specific patient-reported outcome measure which determines the effect rheumatoid arthritis has on a patient’s quality of life.<ref>de Jong, Z.,
The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument., Rheumatology, 1997, Vol. 36(Issue: 8), pp. 878–883, DOI: 10.1093/rheumatology/36.8.878, Full text,</ref> The RAQoL has 30 items with a yes and no response format<ref>Adams, Jo, Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology, Rheumatology, 2013, Vol. 52(Issue: 3), pp. 460–464, DOI: 10.1093/rheumatology/kes296, PMID: 23118412, Full text,</ref> and takes about six minutes to complete.<ref>de Jong, Z., The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument., Rheumatology, 1997, Vol. 36(Issue: 8), pp. 878–883, DOI: 10.1093/rheumatology/36.8.878, Full text,</ref>
Scores on the RAQoL are a sum of all the individual item scores with a range from 0-30, with a lower score indicating better quality of life.<ref>Tijhuis, G.J.,
The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire, Rheumatology, 2001, Vol. 40(Issue: 10), pp. 1112–1119, DOI: 10.1093/rheumatology/40.10.1112, Full text,</ref> The RAQoL is a self-assessment questionnaire, meaning patients fill out the survey themselves in order to avoid experimental error.<ref>Maska, L., Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL)., Arthritis Care & Research, Vol. 63(Issue: Supplement S11), pp. S4–S13, DOI: 10.1002/acr.20620, PMID: 22588760,</ref>
History
The RAQoL was developed by Galen Research, the University of Leeds and the Academic Hospital Maastricht, and was first published in 1997.<ref>Whalley, D.,
Quality of life in rheumatoid arthritis., Rheumatology, 1997, Vol. 36(Issue: 8), pp. 884–888, DOI: 10.1093/rheumatology/36.8.884, Full text,</ref> It was the first patient completed quality of life questionnaire that focused on rheumatoid arthritis <ref>Marra, Carlo A., A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis., Social Science & Medicine, Vol. 60(Issue: 7), pp. 1571–1582, DOI: 10.1016/j.socscimed.2004.08.034, PMID: 15652688,</ref> and is distinct from other questionnaires as it includes physical contact as a dimension of quality of life.<ref>Tijhuis, G.J., The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire, Rheumatology, 2001, Vol. 40(Issue: 10), pp. 1112–1119, DOI: 10.1093/rheumatology/40.10.1112, Full text,</ref> Other dimensions include activities of daily living, social interaction/function, emotions, mood and recreation and pastimes.<ref>Lillegraven, Siri, Measuring disability and quality of life in established rheumatoid arthritis., Best Practice & Research Clinical Rheumatology., Vol. 21(Issue: 5), pp. 827–840, DOI: 10.1016/j.berh.2007.05.004, PMID: 17870030,</ref>
International Use
Since its development, the RAQOL has been translated into 33 languages other than Dutch and UK English.<ref>
Measures Database(link). {{{website}}}. Galen Research.
</ref> Validation studies have been performed in countries such as Sweden,<ref>Eberhardt, Kerstin,
Measuring health related quality of life in patients with rheumatoid arthritis – reliability, validity, and responsiveness of a Swedish version of RAQoL., Scandinavian Journal of Rheumatology, Vol. 31(Issue: 1), pp. 6–12, DOI: 10.1080/030097402317255291, PMID: 11922201,</ref> Argentina<ref>Waimann, Christian A., Quality of life of patients with rheumatoid arthritis in Argentina: reliability, validity, and sensitivity to change of a Spanish version of the Rheumatoid Arthritis Quality of Life questionnaire., Clinical Rheumatology, Vol. 31(Issue: 7), pp. 1065–1071, DOI: 10.1007/s10067-013-2397-x, PMID: 24158632, Full text,</ref> and Australia<ref>Cox, S.R., Adaptation of the RAQoL for use in Australia, Rheumatology International, Vol. 27(Issue: 7), pp. 661–666, DOI: 10.1007/s00296-006-0287-0, PMID: 17195065,</ref> in order to confirm the responsiveness and validity of the language adaptations.
The RAQoL has been used in clinical studies in order to confirm the efficacy of proposed treatments of rheumatoid arthritis. It has been utilized in order to confirm the efficacy of tocilizumab<ref>Dougados, Maxime,
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY), Annals of the Rheumatic Diseases, 2013, Vol. 72(Issue: 1), pp. 43–50, DOI: 10.1136/annrheumdis-2011-201282, PMID: 22562983, PMC: 3551223,</ref><ref>, Efficacy of tocilizumab in patients with rheumatoid arthritis, Current Controlled Trials, DOI: 10.1186/ISRCTN21216199, Full text,</ref> and infliximab.<ref>Quinn, Mark A., Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, Vol. 52(Issue: 1), pp. 27–35, DOI: 10.1002/art.20712, PMID: 15641102,</ref><ref>Bejarano, Victoria, Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis., Rheumatology, 2010, Vol. 49(Issue: 10), pp. 1971–1974, DOI: 10.1093/rheumatology/keq194, PMID: 20595536, Full text,</ref>
References
<references group="" responsive="1"></references>
Ad. Transform your life with W8MD's Budget GLP-1 injections from $49.99


W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $49.99 for the starting dose of Semaglutide and $65.00 for Tirzepatide.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
